Its 503B registration enables bulk production and distribution to clinics and healthcare facilities across the country
In late 2023, the FDA also approved it for chronic weight management for people with obesity (body mass index of 30 kg/m 2 or higher) or overweight (body mass index of 27-29 kg/m 2 ) and at least one weight-related health condition, such as high blood pressure, Type 2 diabetes or high cholesterol
The results of the SURMOUNT-4 clinical trial, published in JAMA , emphasize the need to continue pharmacotherapy to prevent weight regain and ensure improvement in cardiometabolic risk factors
Bezin, J., Gouverneur, A., Pnichon, M., Mathieu, C., Garrel, R., Hillaire-Buys, D., Pariente, A., & Faillie, J
GIP enhances the first phase of insulin release, while GLP-1 sustains the second phase
Oral and sublingual options Oral tirzepatide formulations have gained attention as alternatives to injections